Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice
- PMID: 24275089
- DOI: 10.1016/j.fct.2013.11.015
Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice
Abstract
Yellow pigments monascin (MS) and ankaflavin (AK) are secondary metabolites derived from Monascus-fermented products. The hypolipidemic and anti-inflammatory effects of MS and AK indicate that they have potential on preventing or curing nonalcoholic fatty liver disease (NAFLD). Oleic acid (OA) and high-fat diet were used to induce steatosis in FL83B hepatocytes and NAFLD in mice, respectively. We found that both MS and AK prevented fatty acid accumulation in hepatocytes by inhibiting fatty acid uptake, lipogenesis, and promoting fatty acid beta-oxidation mediated by activating peroxisome proliferator-activated receptor (PPAR)-α and AMP-activated kinase (AMPK). Furthermore, MS and AK significantly attenuated high-fat diet-induced elevation of total cholesterol (TC), triaceylglycerol (TG), free fatty acid (FFA), and low density lipoprotein-cholesterol (LDL-C) in plasma. MS and AK promoted AMPK phosphorylation, suppressed the steatosis-related mRNA expression and inflammatory cytokines secretion, as well as upregulated farnesoid X receptor (FXR), peroxisome proliferator-activated receptor gamma co-activator (PGC)-1α, and PPARα expression to induce fatty acid oxidation in the liver of mice. We provided evidence that MS and AK act as PPARα agonists to upregulate AMPK activity and attenuate NAFLD. MS and AK may be supplied in food supplements or developed as functional foods to reduce the risk of diabetes and obesity.
Keywords: ACC; ACOX; ACS; AK; ALT; AMP-activated kinase; AMPK; AST; Ankaflavin (AK); BSA; CPT-1; CV; DMSO; ELISA; FABP; FAS; FAT; FBS; FFA; FXR; GLUT; H&E; HAECs; HDL-C; HPLC; HUVECs; IACUC; ICAM-1; IL-6; Institutional Animal Care and Use Committee; JNK; LDL-C; MS; MTP; Monascin (MS); NAFLD; NASH; NCBI; NF-κB; National Center for Biotechnology Information; Nonalcoholic fatty liver disease (NAFLD); Nrf2; OA; Oleic acid (OA); PCR; PGC-1α; PPARα; PPARγ; PPREs; PTP1B; Peroxisome proliferator-activated receptor (PPAR)-α; SDS; SPPARMs; SREBP-1c; TC; TG; TGFβ; TLC; TNF-α; TR-FRET; TZDs; Tyr; VCAM-1; acetyl-CoA carboxylase; acyl-CoA oxidase; acyl-CoA synthetase; alanine aminotranferase; ankaflavin; aspartate transaminase; bovine serum albumin; c-Jun NH(2)-terminal kinase; cardiovascular; carnitine palmitoyl transferase I; dimethyl sulfoxide; enzyme-linked immunosorbent assay; farnesoid X receptor; fatty acid synthase; fatty acid transporter; fatty acid-binding protein; fetal bovine serum; free fatty acid; glucose transporter; hematoxylin and eosin; high-density lipoprotein cholesterol; high-performance liquid chromatography; human aortic endothelial cells; human umbilical vein endothelial cells; iNOS; inducible nitric oxide synthase; intercellular adhesion molecule-1; interleukin-6; low density lipoprotein-cholesterol; microsomal triglyceride transfer protein; monascin; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; nuclear factor erythroid 2-related factor 2; nuclear factor-kappaB; oleic acid; peroxisome proliferator activated receptor alpha; peroxisome proliferator activated receptor gamma; peroxisome proliferator-activated receptor gamma co-activator 1-alpha; peroxisome-proliferator-response elements; polymerase chain reaction; protein tyrosine phosphatase 1B; selective PPAR modulators; sodium dodecyl sulfate; sterol regulatory element-binding protein; thiazolidinediones; thin layer chromatography; time-resolved fluorescence resonance energy transfer; total cholesterol; transformation growth factor beta; triaceylglycerol; tumor necrosis factor-alpha; tyrosine; vascular cell adhesion molecule-1.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Similar articles
-
Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.Metabolism. 2013 Nov;62(11):1651-61. doi: 10.1016/j.metabol.2013.06.012. Epub 2013 Aug 5. Metabolism. 2013. PMID: 23928105
-
Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2).Cell Mol Gastroenterol Hepatol. 2017 Dec 13;5(3):367-398. doi: 10.1016/j.jcmgh.2017.11.016. eCollection 2018 Mar. Cell Mol Gastroenterol Hepatol. 2017. PMID: 29552625 Free PMC article.
-
Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1.Food Chem Toxicol. 2013 Aug;58:198-209. doi: 10.1016/j.fct.2013.04.018. Epub 2013 Apr 18. Food Chem Toxicol. 2013. PMID: 23603006
-
Postprandial lipoproteins and the molecular regulation of vascular homeostasis.Prog Lipid Res. 2013 Oct;52(4):446-64. doi: 10.1016/j.plipres.2013.06.001. Epub 2013 Jun 15. Prog Lipid Res. 2013. PMID: 23774609 Review.
-
Free radical biology for medicine: learning from nonalcoholic fatty liver disease.Free Radic Biol Med. 2013 Dec;65:952-968. doi: 10.1016/j.freeradbiomed.2013.08.174. Epub 2013 Aug 29. Free Radic Biol Med. 2013. PMID: 23994574 Review.
Cited by
-
4-O-methylhonokiol protects against diabetic cardiomyopathy in type 2 diabetic mice by activation of AMPK-mediated cardiac lipid metabolism improvement.J Cell Mol Med. 2019 Aug;23(8):5771-5781. doi: 10.1111/jcmm.14493. Epub 2019 Jun 14. J Cell Mol Med. 2019. PMID: 31199069 Free PMC article.
-
Quality and Authenticity Control of Functional Red Yeast Rice-A Review.Molecules. 2019 May 20;24(10):1944. doi: 10.3390/molecules24101944. Molecules. 2019. PMID: 31137594 Free PMC article. Review.
-
Production and biological activities of yellow pigments from Monascus fungi.World J Microbiol Biotechnol. 2016 Aug;32(8):136. doi: 10.1007/s11274-016-2082-8. Epub 2016 Jun 29. World J Microbiol Biotechnol. 2016. PMID: 27357404 Review.
-
Chronic kidney disease in a murine model of non-alcoholic steatohepatitis (NASH).Kidney Int. 2024 Mar;105(3):540-561. doi: 10.1016/j.kint.2023.12.009. Epub 2023 Dec 28. Kidney Int. 2024. PMID: 38159678
-
The Impacts of Herbal Medicines and Natural Products on Regulating the Hepatic Lipid Metabolism.Front Pharmacol. 2020 Mar 24;11:351. doi: 10.3389/fphar.2020.00351. eCollection 2020. Front Pharmacol. 2020. PMID: 32265720 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous